0000000000903244

AUTHOR

Matteo Bassetti

showing 25 related works from this author

Ceftazidime-avibactam use for klebsiella pneumoniae carbapenemase-producing k. pneumoniae infections: A retrospective observational multicenter study

2021

Abstract Background A growing body of observational evidence supports the value of ceftazidime-avibactam (CAZ-AVI) in managing infections caused by carbapenem-resistant Enterobacteriaceae. Methods We retrospectively analyzed observational data on use and outcomes of CAZ-AVI therapy for infections caused by Klebsiella pneumoniae carbapenemase–producing K. pneumoniae (KPC-Kp) strains. Multivariate regression analysis was used to identify variables independently associated with 30-day mortality. Results were adjusted for propensity score for receipt of CAZ-AVI combination regimens versus CAZ-AVI monotherapy. Results The cohort comprised 577 adults with bloodstream infections (n = 391) or nonba…

Microbiology (medical)Adultmedicine.medical_specialtyAzabicyclo CompoundcarbapenemasesBacterial ProteinMicrobial Sensitivity TestsNeutropeniaCeftazidimebeta-Lactamasesbeta-LactamaseCarbapenemasecarbapenemaseBacterial ProteinsRetrospective StudieLower respiratory tract infectionInternal medicineDrug CombinationAnti-Bacterial AgentmedicineHumansKPC-producing Klebsiella pneumoniaeRetrospective StudiesSeptic shockbusiness.industryCeftazidime-avibactamMicrobial Sensitivity Testceftazidime-avibactamMortality rateCarbapenemases; Ceftazidime-avibactam; KPC-producing Klebsiella pneumoniae; Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; Ceftazidime; Drug Combinations; Humans; Microbial Sensitivity Tests; Retrospective Studies; beta-Lactamases; Klebsiella Infections; Klebsiella pneumoniaeKPC-producing Klebsiella pneumoniae; carbapenemases; ceftazidime-avibactammedicine.diseaseCeftazidime/avibactamSettore MED/17KPC-producing Klebsiella pneumoniae; carbapenemases; ceftazidime-avibactam; Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; Ceftazidime; Drug Combinations; Humans; Microbial Sensitivity Tests; Retrospective Studies; beta-Lactamases; Klebsiella Infections; Klebsiella pneumoniaeAnti-Bacterial AgentsKlebsiella InfectionsDrug CombinationsKlebsiella pneumoniaeInfectious DiseasesCohortPropensity score matchingObservational studybusinessAzabicyclo Compoundsmedicine.drugHumanKlebsiella Infection
researchProduct

Zygomycosis in Italy: A survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology)

2009

Abstract The aims of the study were to analyze the clinical and epidemiological characteristics and treatments for patients who developed zygomycosis enrolled in Italy during the European Confederation of Medical Mycology of medical mycology survey. This prospective multicenter study was performed between 2004 and 2007 at 49 italian Departments. 60 cases of zygomycosis were enrolled: the median age was 59.5 years (range 1-87), with a prevalence of males (70%). The majority of cases were immunocompromised patients (42 cases, 70%), mainly hematological malignancies (37). Among non-immunocompromised (18 cases, 30%), the main category was represented by patients with penetrating trauma (7/18, 3…

AdultMalemedicine.medical_specialtyAdolescentEpidemiologyAntifungal drugImmunocompromised HostPharmacotherapyZygomycosisDrug Resistance FungalAmphotericin BInternal medicineEpidemiologymedicineHumansPharmacology (medical)ChildMycosisAgedPharmacologyImmunocompromised hostAged 80 and overbusiness.industryMortality rateMucormycosisInfantEpidemiology; Immunocompromised host; ZygomycosisMiddle Agedmedicine.diseaseSurgeryInfectious DiseasesOncologyItalyChild PreschoolFemaleZygomycosisbusinessmedicine.drug
researchProduct

Procalcitonin levels in candidemia versus bacteremia: a systematic review

2019

Background Procalcitonin (PCT) is a biomarker used to assess systemic inflammation, infection, and sepsis and to optimize antimicrobial therapies. Its role in the in the differential diagnosis between candidemia and bacteremia is unclear. The aim of this systematic review was to summarize the current evidence about PCT values for differentiating candidemia from bacteremia. Methods PubMed and EMBASE were searched for studies reporting data on the diagnostic performance of serum PCT levels in intensive care unit (ICU) or non-ICU adult patients with candidemia, in comparison to patients with bacteremia. Results We included 16 studies for a total of 45.079 patients and 785 cases of candidemia. …

AdultMaleCalcitoninmedicine.medical_specialtyLetterBacteremiaCritical Care and Intensive Care MedicineProcalcitoninlaw.inventionSepsis03 medical and health sciences0302 clinical medicineBiomarker; Candida; Candidemia; Fungal; Fungi; PCT; Procalcitonin; SepsislawSecondary analysisSepsisparasitic diseasesmedicineHumansIntensive care medicineCandidaAdult patientsbusiness.industryResearchlcsh:Medical emergencies. Critical care. Intensive care. First aidFungiCandidemia030208 emergency & critical care medicinelcsh:RC86-88.9Biomarkermedicine.diseasebacterial infections and mycosesIntensive care unitFungalBacteremiaBiomarker (medicine)FemaleDifferential diagnosisbusinessPCTProcalcitoninhormones hormone substitutes and hormone antagonistsBiomarkersCritical Care
researchProduct

Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, adult patients: A systematic review with…

2020

Contains fulltext : 229471.pdf (Publisher’s version ) (Closed access) OBJECTIVES: To summarize the available evidence on the diagnostic performance for invasive aspergillosis (IA) in non-hematological, non-solid organ transplantation critically ill patients of the following: (i) existing definitions of IA (developed either for classical immunocompromised populations or for non-immunocompromised critically ill patients); (ii) laboratory tests; (iii) radiology tests. METHODS: A systematic review was performed by evaluating studies assessing the diagnostic performance for IA of a definition/s and/or laboratory/radiology test/s vs. a reference standard (histology) or a reference definition. RES…

0301 basic medicineMicrobiology (medical)Adultmedicine.medical_specialtyCritical Illness030106 microbiologyAspergillosisSensitivity and SpecificityOrgan transplantationMannans03 medical and health sciencesGalactomannanchemistry.chemical_compound0302 clinical medicineDiagnosisMedicineHumansAspergillosis030212 general & internal medicineIntensive care medicineInvasive Pulmonary AspergillosisAdult patientsmedicine.diagnostic_testbusiness.industryCritically illIABiomarkerInvasive pulmonary aspergillosismedicine.diseaseAspergillulnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]Infectious DiseasesBronchoalveolar lavageAspergilluschemistryIPAAspergillus; Biomarker; Diagnosis; IA; IPA; Invasive aspergillosis; Adult; Bronchoalveolar Lavage Fluid; Critical Illness; Humans; Mannans; Sensitivity and Specificity; Aspergillosis; Invasive Pulmonary AspergillosisBiomarker (medicine)Aspergillus; Biomarker; Diagnosis; IA; Invasive aspergillosis; IPA; Adult; Bronchoalveolar Lavage Fluid; Critical Illness; Humans; Mannans; Sensitivity and Specificity; Aspergillosis; Invasive Pulmonary AspergillosisInvasive aspergillosisbusinessBronchoalveolar Lavage FluidDiagnosi
researchProduct

Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project

2019

Contains fulltext : 206779.pdf (Publisher’s version ) (Open Access) BACKGROUND: The objective of this study was to assess the cumulative incidence of invasive candidiasis (IC) in intensive care units (ICUs) in Europe. METHODS: A multinational, multicenter, retrospective study was conducted in 23 ICUs in 9 European countries, representing the first phase of the candidemia/intra-abdominal candidiasis in European ICU project (EUCANDICU). RESULTS: During the study period, 570 episodes of ICU-acquired IC were observed, with a cumulative incidence of 7.07 episodes per 1000 ICU admissions, with important between-center variability. Separated, non-mutually exclusive cumulative incidences of candide…

MaleOutcome Assessmentlnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4]MULTICENTERCritical Care and Intensive Care Medicinelaw.invention610 Medical sciences Medicine0302 clinical medicineRetrospective StudieRisk FactorslawOutcome Assessment Health CareEPIDEMIOLOGYMedicineCumulative incidencePREDICTORSCandidaMedicine(all)Cross InfectionIncidenceIncidence (epidemiology)lcsh:Medical emergencies. Critical care. Intensive care. First aidCandidiasisMiddle AgedIntensive care unitEuropeIntensive Care UnitsAbdominal candidiasis; Candida; Candidemia; Candidiasis; ICU; Incidence; Aged; Candidiasis Invasive; Cross Infection; Europe; Female; Humans; Incidence; Intensive Care Units; Male; Middle Aged; Outcome Assessment Health Care; Retrospective Studies; Risk FactorsCandidiasiFemaleSOFA scoreLife Sciences & BiomedicineHumanAbdominal candidiasismedicine.medical_specialtyInvasiveIntensive Care Unit610Abdominal candidiasis Candida Candidemia Candidiasis ICU Incidence03 medical and health sciencesCritical Care MedicineGeneral & Internal MedicineIntensive careSettore MED/41 - ANESTESIOLOGIAMANAGEMENTHumansCandidiasis InvasiveAgedRetrospective StudiesScience & TechnologyAbdominal candidiasis; Candida; Candidemia; Candidiasis; ICU; Incidencebusiness.industrySeptic shockINTRAABDOMINAL CANDIDIASISResearchCandidemia030208 emergency & critical care medicineRetrospective cohort studylcsh:RC86-88.9Odds ratiomedicine.diseaseHealth Carelnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]ICUEmergency medicineAbdominal candidiasibusinessCritical Care
researchProduct

Corrigendum to “Personal protective equipment and intensive care unit healthcare worker safety in the COVID-19 Era (PPE-SAFE): An international surve…

2021

The authors regret errors were present in the published article. Counts of some of the adverse events were erroneous. Changes to the text include. Last sentence of the abstract should read. Adverse effects of PPE included heat (1266, 51%), thirst (1174, 47%), pressure areas (1088, 44%), headaches (696, 28%), Inability to use the bathroom (661, 27%) and extreme exhaustion (492, 20%). All but pressure areas were associated with longer shift durations. Last sentence of the results section of the manuscript should read. All but pressure areas were associated with longer duration of shifts wearing PPE (Table 4). Table 1 the total number of community/urban type of hospital should read 740 instead…

Extreme exhaustionCoronavirus disease 2019 (COVID-19)masks COVID19business.industryMEDLINEInternational surveyHealthcare worker030208 emergency & critical care medicineRegretmedicine.diseaseCritical Care and Intensive Care MedicineIntensive care unitlaw.invention03 medical and health sciences0302 clinical medicine030228 respiratory systemlawMedicineMedical emergencyCorrigendumbusinessPersonal protective equipmentJournal of Critical Care
researchProduct

Personal protective equipment and intensive care unit healthcare worker safety in the COVID-19 era (PPE-SAFE): An international survey

2020

Purpose To survey healthcare workers (HCW) on availability and use of personal protective equipment (PPE) caring for COVID-19 patients in the intensive care unit (ICU). Materials and method A web-based survey distributed worldwide in April 2020. Results We received 2711 responses from 1797 (67%) physicians, 744 (27%) nurses, and 170 (6%) Allied HCW. For routine care, most (1557, 58%) reportedly used FFP2/N95 masks, waterproof long sleeve gowns (1623; 67%), and face shields/visors (1574; 62%). Powered Air-Purifying Respirators were used routinely and for intubation only by 184 (7%) and 254 (13%) respondents, respectively. Surgical masks were used for routine care by 289 (15%) and 47 (2%) for…

Face shieldMalebusiness.product_categoryHot TemperatureInfectious Disease TransmissionAllied Health PersonnelNursesCritical Care and Intensive Care MedicineOccupational safety and healthlaw.inventionPatient-to-Professional0302 clinical medicinelawSurveys and QuestionnairesPersonal protective equipmentHealth careMedicine and Health SciencesViralRespiratorRespiratory Protective DevicesHealth care workersHealth services researchHeadacheMasksMiddle AgedIntensive care unitEuropeIntensive Care UnitsFemaleSafetyCoronavirus InfectionsEye Protective DevicesThirstAdultmedicine.medical_specialtyCOVID-19; Health care workers; Intensive care; Personal protective equipment; Safety; Adult; Africa; Allied Health Personnel; Asia; Betacoronavirus; COVID-19; Coronavirus Infections; Europe; Eye Protective Devices; Female; Gloves Protective; Headache; Hot Temperature; Humans; Infectious Disease Transmission Patient-to-Professional; Intensive Care Units; Male; Masks; Middle Aged; North America; Nurses; Oceania; Pandemics; Personal Protective Equipment; Personnel Staffing and Scheduling; Physicians; Pneumonia Viral; Respiratory Protective Devices; SARS-CoV-2; South America; Surgical Attire; Surveys and Questionnaires; Thirst; Health Personnel; Occupational HealthInfectious Disease Transmission Patient-to-ProfessionalAsiaHealth PersonnelPneumonia ViralGlovesOceaniaPersonnel Staffing and SchedulingArticle03 medical and health sciencesBetacoronavirusIntensive carePhysiciansmedicineHumansSurgical AttirePersonal protective equipmentPandemicsOccupational Healthbusiness.industrySARS-CoV-2COVID-19030208 emergency & critical care medicinePneumoniaSouth AmericaProtective030228 respiratory systemCOVID-19Personal protective equipmentSafety Health care workersIntensive careIntensive careEmergency medicineAfricaNorth AmericabusinessGloves ProtectiveJournal of Critical Care
researchProduct

Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, non-neutropenic, adult patients: An upda…

2022

Microbiology (medical)AdultInvasive Pulmonary AspergillosisIntensive Care UnitsAspergillusInfectious DiseasesCOVID-19 TestingCritical IllnessAspergillosisCOVID-19HumansSettore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICAInvasive Fungal InfectionsThe Journal of infection
researchProduct

Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing Klebsiella pneumoniae: a multicentre study

2022

Abstract Objectives To explore the real-life performance of meropenem/vaborbactam for treating serious KPC-producing Klebsiella pneumoniae infections, including those resistant to ceftazidime/avibactam. Methods A retrospective observational cohort study was conducted in 12 Italian hospitals. Enrolled patients had K. pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-Kp) infections (59.5% of which were ceftazidime/avibactam resistant). Patients who received ≥72 h of meropenem/vaborbactam therapy (with or without other antimicrobials) in a compassionate-use setting were included. Results The 37 infections (all hospital-acquired) were mainly bacteraemic (BSIs, n = 23) or lower respira…

meropenemKPC-producing Klebsiella pneumoniae infectionMeropenem vaborbactamvaborbactam.
researchProduct

How to manage aspergillosis in non-neutropenic intensive care unit patients.

2014

Invasive aspergillosis has been mainly reported among immunocompromised patients during prolonged periods of neutropenia. Recently, however, non-neutropenic patients in the ICU population have shown an increasing risk profile for aspergillosis. Associations with chronic obstructive pulmonary disease and corticosteroid therapy have been frequently documented in this cohort. Difficulties in achieving a timely diagnosis of aspergillosis in non-neutropenic patients is related to the non-specificity of symptoms and to lower yields with microbiological tests compared to neutropenic patients. Since high mortality rates are typical of invasive aspergillosis in critically ill patients, a high level …

medicine.medical_specialtyPediatricsChronic ObstructiveAntifungal AgentsCritical IllnessPopulationPulmonary diseaseSettore MED/41 - AnestesiologiaReviewNeutropeniaOpportunistic InfectionsAspergillosisCritical Care and Intensive Care MedicineCommunicable DiseasesCommunicable Diseases Emerginglaw.inventionPulmonary DiseaseImmunocompromised HostPulmonary Disease Chronic ObstructiveAspergillosis non-neutropenic ICUlawAdrenal Cortex HormonesRisk FactorsEpidemiologymedicinenon-neutropenicPrevalenceAspergillosisHumansIntensive care medicineeducationEmergingeducation.field_of_studybusiness.industryIncidence (epidemiology)Medicine (all)IncidenceAdrenal Cortex Hormones; Antifungal Agents; Aspergillosis; Communicable Diseases Emerging; Critical Illness; Humans; Incidence; Intensive Care Units; Opportunistic Infections; Prevalence; Prognosis; Pulmonary Disease Chronic Obstructive; Risk Factors; Immunocompromised Host; Critical Care and Intensive Care Medicinemedicine.diseasePrognosisIntensive care unitAdrenal Cortex Hormones; Antifungal Agents; Aspergillosis; Communicable Diseases Emerging; Critical Illness; Humans; Incidence; Intensive Care Units; Opportunistic Infections; Prevalence; Prognosis; Pulmonary Disease Chronic Obstructive; Risk Factors; Immunocompromised HostIntensive Care UnitsCohortICUAdrenal Cortex Hormones; Antifungal Agents; Aspergillosis; Communicable Diseases Emerging; Critical Illness; Humans; Incidence; Intensive Care Units; Opportunistic Infections; Prevalence; Prognosis; Pulmonary Disease Chronic Obstructive; Risk Factors; Immunocompromised Host; Critical Care and Intensive Care Medicine; Medicine (all)businesssepsis aspergillosis icu managementCritical care (London, England)
researchProduct

Personal protective equipment use by healthcare workers in intensive care unit during the early phase of COVID-19 pandemic in Italy: a secondary anal…

2021

Background: Italy was the first Western country to be heavily affected by COVID-19. Healthcare workers (HCWs) were exposed to a high risk of occupational infection, partially due to insufficient personal protective equipment (PPE) supplies. This study aimed to describe the practices, availability, training, confidence in PPE use and the adverse effects due to extended PPE use, as reported by HCWs in Italy. We also aimed to provide a comparison between Italian data and those from other countries. Methods: This study was a secondary analysis of a previously published international study, the PPE-SAFE Survey, conducted in April 2020. Data were analysed from the original study database. Results…

Coronavirus disease 2019 (COVID-19)Infectious and parasitic diseasesRC109-21601 natural scienceslaw.invention03 medical and health sciences0302 clinical medicinePatient satisfactionlawEnvironmental healthSecondary analysisPandemicHealth careMedicinePharmacology (medical)survey030212 general & internal medicine0101 mathematicsPersonal protective equipmentOriginal Researchbusiness.industry010102 general mathematicsCOVID-19Intensive care unitInfectious DiseasesItalypersonal protective equipmentbusinessEarly phasePPE-SAFETherapeutic advances in infectious disease
researchProduct

Estimating minimum adult HIV prevalence: A cross-sectional study to assess the characteristics of people living with HIV in Italy

2015

In 2012, we conducted a retrospective cross-sectional study to assess the number of people living with HIV linked to care and, among these, the number of people on antiretroviral therapy. The health authority in each of the 20 Italian Regions provided the list of Public Infectious Diseases Clinics providing antiretroviral therapy and monitoring people with HIV infection. We asked every Public Infectious Diseases Clinic to report the number of HIV-positive people diagnosed and linked to care and the number of those on antiretroviral therapy during 2012. In 2012, 94,146 people diagnosed with HIV and linked to care were reported. The majority were males (70.1%), Italians (84.4%), and aged betw…

AdultMalePediatricsmedicine.medical_specialtyImmunology; Infectious Diseases; VirologySettore MED/17 - Malattie InfettiveEpidemiologyCross-sectional studyImmunologyHuman immunodeficiency virus (HIV)MEDLINEHIV Infectionsmedicine.disease_causeAdult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Female; HIV Infections; Humans; Italy; Male; Middle Aged; Prevalence; Retrospective StudiesVirologymedicinePrevalenceHumansHIV InfectionHIV prevalence ItalyRetrospective StudiesCross-Sectional StudieAdult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Female; HIV Infections; Humans; Italy; Male; Middle Aged; Prevalence; Retrospective Studies; Immunology; Virology; Infectious Diseasesbusiness.industryTransmission (medicine)HIVRetrospective cohort studyMiddle AgedHiv prevalenceNorthern italyCD4 Lymphocyte CountCross-Sectional StudiesInfectious DiseasesAnti-Retroviral AgentsItalyAnti-Retroviral AgentFemalebusinessViral loadHumanDemography
researchProduct

Ventilatory associated barotrauma in COVID-19 patients: A multicenter observational case control study (COVI-MIX-study)

2022

Background The risk of barotrauma associated with different types of ventilatory support is unclear in COVID- 19 patients. The primary aim of this study was to evaluate the effect of the different respiratory support strategies on barotrauma occurrence; we also sought to determine the frequency of barotrauma and the clinical characteristics of the patients who experienced this complication. Methods This multicentre retrospective case-control study from 1 March 2020 to 28 February 2021 included COVID-19 patients who experienced barotrauma during hospital stay. They were matched with controls in a 1:1 ratio for the same admission period in the same ward of treatment. Univariable and multivari…

Pulmonary and Respiratory MedicineHigh flow nasal cannulaAcute respiratory failure; Barotrauma; COVID-19; High flow nasal cannula; Invasive mechanical ventilation; PneumothoraxBarotraumaCOVID-19PneumothoraxInvasive mechanical ventilationAcute respiratory failure
researchProduct

The global challenge of Candida auris in the intensive care unit

2019

Since the first isolation of Candida auris in 2009, scientific community has witnessed an exponential emergence of infection episodes and outbreaks in different world regions. It is hard to predict future C. auris diffusion. By now, global surveillance, improving knowledge, and taking care of the A.U.R.I.S. major issues may be the best ways to face C. auris challenge

medicine.medical_specialtyCritical Care Intensive Care Medicine Candida aurisbusiness.industryIatrogenic DiseaseMEDLINElcsh:Medical emergencies. Critical care. Intensive care. First aidCandidiasisCandida; Candidiasis; Global Health; Humans; Iatrogenic Disease; Intensive Care Unitslcsh:RC86-88.9Critical Care and Intensive Care MedicineGlobal HealthIntensive care unitlaw.inventionIntensive Care UnitsEditorialCandida aurislawMedicineHumansbusinessIntensive care medicineCandidaCritical Care
researchProduct

Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapene…

2020

Background: Experience in real clinical practice with ceftazidime-avibactam for the treatment of serious infections due to gram&minus

Nosocomial pneumonia0301 basic medicineMicrobiology (medical)medicine.medical_specialtymedicine.drug_classmedicine.medical_treatment030106 microbiologyAntibioticscarbapenem-sparing regimenBiologymedicine.disease_causeBiochemistryMicrobiologyArticleCarbapenem-sparing regimen; Ceftazidime-avibactam; ESBL-producing Enterobacterales; Nosocomial pneumonia; Pseudomonas aeruginosa03 medical and health sciences0302 clinical medicineESBL-producing EnterobacteralesCarbapenem-sparing regimenInternal medicinemedicinePharmacology (medical)030212 general & internal medicineRenal replacement therapyGeneral Pharmacology Toxicology and PharmaceuticsRisk factorAdverse effectESBL-producing Enterobacterales; Pseudomonas aeruginosa; carbapenem-sparing regimen; ceftazidime-avibactam; nosocomial pneumoniaCeftazidime-avibactamPseudomonas aeruginosaceftazidime-avibactamnosocomial pneumonialcsh:RM1-950medicine.diseaseCeftazidime/avibactamPneumonialcsh:Therapeutics. PharmacologyInfectious DiseasesEndocrinologyBacteremiaPseudomonas aeruginosaESBL-producing Enterobacteralemedicine.drugAntibiotics
researchProduct

Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER …

2021

Background: Direct-acting antivirals are highly effective for the treatment of hepatitis C virus (HCV) infection, regardless race/ethnicity. We aimed to evaluate demographic, virological and clinical data of HCV-infected migrants vs. natives consecutively enrolled in the PITER cohort. Methods: Migrants were defined by country of birth and nationality that was different from Italy. Mann-Whitney U test, Chi-squared test and multiple logistic regression were used. Results: Of 10,669 enrolled patients, 301 (2.8%) were migrants: median age 47 vs. 62 years, (p < 0.001), females 56.5% vs. 45.3%, (p < 0.001), HBsAg positivity 3.8% vs. 1.4%, (p < 0.05). Genotype 1b was prevalent in both gro…

MaleHCV genotypesEthnic groupLinked-to-care patientComorbidityHepacivirusLogistic regressionmedicine.disease_causeComorbidities; Direct acting antivirals; HCV Cohort; Linked-to-care patients; Aged; Antiviral Agents; Coinfection; Comorbidity; Female; Hepacivirus; Hepatitis C Chronic; Humans; Italy; Male; Middle Aged; Transients and MigrantsComorbidities0302 clinical medicineMedicineComorbidities; Direct acting antivirals; HCV Cohort; Linked-to-care patientsChronicTransients and MigrantsCoinfectionGastroenterologyvirus diseasesMiddle AgedHepatitis CLife evaluationItaly030220 oncology & carcinogenesisLinked-to-care patientsCohort030211 gastroenterology & hepatologyFemaleComorbiditieHumanHepatitis C virusSettore MED/12 - GASTROENTEROLOGIAAntiviral AgentsDirect acting antivirals03 medical and health sciencesDisease severityHumansAgedAntiviral AgentHepaciviruHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNAHepatitis C Chronicmedicine.diseaseComorbiditydigestive system diseasesDirect acting antiviralHCV CohortbusinessDemography
researchProduct

The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives

2021

INTRODUCTION: The COVID-19 pandemic has dramatically challenged the national health systems worldwide in the last months. Dalbavancin is a novel antibiotic with a long plasmatic half-life and simplified weekly administration regimens, thus representing a promising option for the outpatient treatment of Gram-positive infections and the early discharge of hospitalized patients. Dalbavancin is approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). Many preliminary data seem to support its use in other indications, such as osteomyelitis, prosthetic joint infections, and infective endocarditis. AREAS COVERED: A search in the literature using validated keyword…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)medicine.drug_classProsthetic joint030106 microbiologyAntibioticsGram-Positive Bacterial InfectionABSSSIsMicrobiologyDrug Administration Scheduleosteomyelitis.endocarditi03 medical and health sciencesABSSSIs; COVID-19; dalbavancin; endocarditis; Gram-positive; long-acting; osteomyelitisGram-positive0302 clinical medicineVirologyPandemicAnti-Bacterial AgentmedicineAmbulatory CareAnimalsHumans030212 general & internal medicineIntensive care medicineGram-Positive Bacterial Infectionsbusiness.industryAnimalOsteomyelitisDalbavancinCOVID-19osteomyelitisSkin Diseases Bacteriallong-actingABSSSImedicine.diseaseAnti-Bacterial AgentsInfectious DiseasesInfective endocarditisSkin structureendocarditisosteomyelitiTeicoplaninbusinessdalbavancinHuman
researchProduct

sj-pdf-1-tai-10.1177_2049936121998562 – Supplemental material for Personal protective equipment use by healthcare workers in intensive care unit duri…

2021

Supplemental material, sj-pdf-1-tai-10.1177_2049936121998562 for Personal protective equipment use by healthcare workers in intensive care unit during the early phase of COVID-19 pandemic in Italy: a secondary analysis of the PPE-SAFE survey by Mariachiara Ippolito, Mahesh Ramanan, Davide Bellina, Giulia Catalisano, Pasquale Iozzo, Andrea Di Guardo, Alessandra Moscarelli, Giacomo Grasselli, Antonino Giarratano, Matteo Bassetti, Alexis Tabah and Andrea Cortegiani in Therapeutic Advances in Infectious Disease

110203 Respiratory Diseases111099 Nursing not elsewhere classifiedFOS: Clinical medicine111799 Public Health and Health Services not elsewhere classifiedFOS: Health sciences111403 Paediatrics111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
researchProduct

sj-pdf-2-tai-10.1177_2049936121998562 – Supplemental material for Personal protective equipment use by healthcare workers in intensive care unit duri…

2021

Supplemental material, sj-pdf-2-tai-10.1177_2049936121998562 for Personal protective equipment use by healthcare workers in intensive care unit during the early phase of COVID-19 pandemic in Italy: a secondary analysis of the PPE-SAFE survey by Mariachiara Ippolito, Mahesh Ramanan, Davide Bellina, Giulia Catalisano, Pasquale Iozzo, Andrea Di Guardo, Alessandra Moscarelli, Giacomo Grasselli, Antonino Giarratano, Matteo Bassetti, Alexis Tabah and Andrea Cortegiani in Therapeutic Advances in Infectious Disease

110203 Respiratory Diseases111099 Nursing not elsewhere classifiedFOS: Clinical medicine111799 Public Health and Health Services not elsewhere classifiedFOS: Health sciences111403 Paediatrics111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
researchProduct

Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic an…

2016

Objectives: We utilized the database of the Defining Antibiotic Levels in Intensive care unit patients (DALI) study to statistically compare the pharmacokinetic/pharmacodynamic and clinical outcomes between prolonged- infusion and intermittent-bolus dosing of piperacillin/tazobactam and meropenem in critically ill patients using inclusion criteria similar to those used in previous prospective studies. Methods: This was a post hoc analysis of a prospective, multicentre pharmacokinetic point-prevalence study (DALI), which recruited a large cohort of critically ill patients from 68 ICUs across 10 countries. Results: Of the 211 patients receiving piperacillin/tazobactam and meropenem in the DAL…

0301 basic medicineMalePenicillanic Acidintensive care unitlaw.inventionthienamycin derivative abdominal infection[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseaseslawcentral nervous system infectioncreatinine clearancePharmacology (medical)Infusions IntravenouProspective StudiesInfusions IntravenousProspective cohort studyTazobactam Drug CombinationAged; Anti-Bacterial Agents; Blood Chemical Analysis; Critical Illness; Female; Humans; Infusions Intravenous; Intensive Care Units; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin Tazobactam Drug Combination; Prospective Studies; Thienamycins; Treatment Outcome; Pharmacology; Microbiology (medical); Pharmacology (medical); Infectious Diseasescritical illneMicrobial Sensitivity TestadultRespiratory infectionclinical trialMiddle Agedcontinuous infusionanalogs and derivativeIntensive care unit3. Good healthAnti-Bacterial Agentsantiinfective agentintravenous drug administrationIntensive Care Units[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyTreatment OutcomeInfectious DiseasesPiperacillin/tazobactammulticenter study (topic)SOFA scoreFemaletreatment outcome AgedIntravenousprospective studyHumanmedicine.drugsurvival rateMicrobiology (medical)medicine.medical_specialtyInfusionspost hoc analysirespiratory tract infectionCritical IllnessAged; Anti-Bacterial Agents; Blood Chemical Analysis; Critical Illness; Female; Humans; Infusions Intravenous; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Thienamycins; Treatment Outcome; Pharmacology; Pharmacology (medical); Infectious Diseases030106 microbiologybloodstream infectionMicrobial Sensitivity Testsminimum inhibitory concentrationpiperacillin plus tazobactamMeropenemTazobactamArticle03 medical and health sciencescritically ill patientInternal medicineAnti-Bacterial AgentmedicineSequential Organ Failure Assessment ScoreHumansThienamycinsurvival timeblood analysiAgedPiperacillinPharmacologybusiness.industryBlood Chemical AnalysiMeropenemmajor clinical studySurgeryProspective Studiemulticenter studyPharmacology; Pharmacology (medical); Infectious Diseases[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyThienamycinspiperacillin tazobactam drug combinationurinary tract infectionbusinessBlood Chemical AnalysisPiperacillin
researchProduct

Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study

2022

INTRODUCTION: Intra-abdominal infections represent the second most frequently acquired infection in the intensive care unit (ICU), with mortality rates ranging from 20% to 50%. Candida spp. may be responsible for up to 10-30% of cases. This study assesses risk factors for development of intra-abdominal candidiasis (IAC) among patients admitted to ICU. METHODS: We performed a case-control study in 26 European ICUs during the period January 2015-December 2016. Patients at least 18 years old who developed an episode of microbiologically documented IAC during their stay in the ICU (at least 48 h after admission) served as the case cohort. The control group consisted of adult patients who did no…

Microbiology (medical)MORTALITYInvasive candidiasiCandida; Intra-abdominal infection; Invasive candidiasis; Risk factorsCONTROLLED-TRIALCASPOFUNGINCANDIDEMIAInvasive candidiasisInfectious Diseaseslnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]Intra-abdominal infectionRisk factorsINFECTIONSMANAGEMENTEPIDEMIOLOGYPREDICTORSCONSENSUSCRITICALLY III PATIENTSCandida
researchProduct

Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study.

2023

Purpose: In the critically ill, hospital-acquired bloodstream infections (HA-BSI) are associated with significant mortality. Granular data are required for optimizing management, and developing guidelines and clinical trials. Methods: We carried out a prospective international cohort study of adult patients (≥ 18 years of age) with HA-BSI treated in intensive care units (ICUs) between June 2019 and February 2021. Results: 2600 patients from 333 ICUs in 52 countries were included. 78% HA-BSI were ICU-acquired. Median Sequential Organ Failure Assessment (SOFA) score was 8 [IQR 5; 11] at HA-BSI diagnosis. Most frequent sources of infection included pneumonia (26.7%) and intravascular catheters…

antibiotic resistancebloodstream infectionhospital-acquiredbacteremiaCritical Care and Intensive Care Medicineantibiotic resistance ; bacteremia ; bloodstream infection ; hospital-acquired.
researchProduct

Additional file 1: of Procalcitonin levels in candidemia versus bacteremia: a systematic review

2019

Search output from PubMed. Full search output from PubMed. (DOCX 299 kb)

researchProduct

Additional file 2: of Procalcitonin levels in candidemia versus bacteremia: a systematic review

2019

Search output from EMBASE. Full search output from EMBASE. (DOCX 88 kb)

researchProduct

Different epidemiology of bloodstream infections in COVID-19 compared to non-COVID-19 critically ill patients: a descriptive analysis of the Eurobact…

2022

Funder: European society of Intensive Care Medicine

Malebloodstream infections:Other subheadings::Other subheadings::/epidemiology [Other subheadings]Critical IllnessCOVID-19 (Malaltia) - EpidemiologiaRESISTANT ENTEROCOCCIBacteremiaBloodstream infectionCritical Care and Intensive Care Medicine:Pathological Conditions Signs and Symptoms::Pathologic Processes::Disease Attributes::Critical Illness [DISEASES]Cohort Studies:afecciones patológicas signos y síntomas::procesos patológicos::atributos de la enfermedad::enfermedad crítica [ENFERMEDADES]Sepsis:virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES]Medicine and Health SciencesHumansNCT03937245Unitats de cures intensivesAgedCross InfectionMalalties bacterianes:infecciones bacterianas y micosis::infección::infección hospitalaria [ENFERMEDADES]Research:Otros calificadores::Otros calificadores::/epidemiología [Otros calificadores]Bacteremia; Bloodstream infection; COVID-19; Enterococcus; ICU-acquiredCOVID-19:Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES]:Bacterial Infections and Mycoses::Infection::Cross Infection [DISEASES]Intensive Care UnitsNCTICURNAICU-acquiredEnterococcus
researchProduct